Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;47(10):931-940.
doi: 10.1007/s40264-024-01447-z. Epub 2024 Jun 28.

Use of the Sentinel System to Examine Medical Product Use and Outcomes During Pregnancy

Affiliations
Review

Use of the Sentinel System to Examine Medical Product Use and Outcomes During Pregnancy

Jennifer G Lyons et al. Drug Saf. 2024 Oct.

Abstract

While many pregnant individuals use prescription medications, evidence supporting product safety during pregnancy is often inadequate. Existing electronic healthcare data sources provide large, diverse samples of health plan members to allow for the study of medical product utilization during pregnancy, as well as pregnancy, maternal, and infant outcomes. The Sentinel System is a national medical product surveillance system that includes administrative claims and electronic health record databases from large national and regional health insurers. In addition to these data sources, Sentinel develops and maintains a sizeable selection of analytic tools to facilitate epidemiologic analyses in a way that protects patient privacy and health system autonomy. In this article, we provide an overview of Sentinel System infrastructure, including the Mother-Infant Linkage Table, parameterizable analytic tools, and algorithms to estimate gestational age and identify pregnancy outcomes. We also describe past and future Sentinel work that contributes to our understanding of the way medical products are used and the safety of these products during pregnancy.

PubMed Disclaimer

References

    1. van der Graaf R, van der Zande ISE, den Ruijter HM, Oudijk MA, van Delden JJM, Oude Rengerink K, et al. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials. 2018;19:78. https://doi.org/10.1186/s13063-017-2402-9 . - DOI - PubMed - PMC
    1. Lupattelli A, Trinh NTH, Nordeng H. Association of maternal personality traits with medication use during pregnancy to appraise unmeasured confounding in long-term pharmacoepidemiological safety studies. Front Pharmacol. 2023;14:1160168. https://doi.org/10.3389/fphar.2023.1160168 . - DOI - PubMed - PMC
    1. Kazma JM, Van Den Anker J, Ahmadzia HK. Pharmacoethics and pregnancy: overcoming the therapeutic orphan stigma. Br J Clin Pharmacol. 2023;89:483–90. https://doi.org/10.1111/bcp.15173 . - DOI - PubMed
    1. Casella C, Lo Giudice M, Niola M, Di Lorenzo P, Adamo M, Bianco C, et al. Need for fair inclusion of pregnant women in clinical trials: scientific and ethical considerations about the lesson from the COVID-19 vaccines development. Minerva Obstet Gynecol. 2022. https://doi.org/10.23736/S2724-606X.21.04922-8 . - DOI - PubMed
    1. Rabinowitz LG, Rabinowitz DG, Silver EM, Oxentenko AS, Williams KE, Silver JK. Disparities persist in inclusion of female, pregnant, lactating, and older individuals in inflammatory bowel disease clinical trials. Gastroenterology. 2022. https://doi.org/10.1053/j.gastro.2022.03.016 . - DOI - PubMed

LinkOut - more resources